U.S., May 29 -- ClinicalTrials.gov registry received information related to the study (NCT07612488) titled 'A Study of CS231295 in Patients With Advanced Solid Tumors' on May 20.
Brief Summary: This is a Phase I, single-arm, open-label, dose-escalation, multicenter clinical study of CS231295 in patients with advanced solid malignant tumors.
Eligible patients must be 18 years or older and have histologically or cytologically confirmed unresectable advanced, recurrent, or metastatic solid tumors, who have failed or are intolerant to previous standard treatments and currently have no other standard treatment options available. Patients should have at least one measurable target lesion (glioma, according to RANO 2.0; other solid tumors accord...